Articles related to CHRONIC DISEASE MANAGEMENT

Two prospective cohorts found that metabolically unhealthy adults generally had higher dementia risk estimates regardless of obesity status. Metabolically healthy obesity was not associated with increased dementia risk in primary analyses, though findings varied across sensitivity analyses.

A national physician survey found rising intent to leave practice alongside increasing chronic care demands and persistent income stagnation across settings.

Two Lilly-sponsored placebo-controlled trials found that adults who transitioned from high-dose injectable GLP-1 therapy to either oral tirzepatide (Foundayo) or a reduced 5 mg tirzepatide maintenance dose preserved most of their prior weight loss over one year, compared to substantial regain in placebo arms.

A Cureus case report describes complete fecaloma resolution after two 1 L Classic Coca-Cola enemas in an 82-year-old woman with dementia whose impaction failed conservative management.

A post hoc SURPASS-CVOT analysis associated tirzepatide with fewer six-component cardiorenal events than dulaglutide in patients with type 2 diabetes and established ASCVD.

“There is enormous exuberance about starting GLP-1 drugs, but not nearly enough attention to what happens when people stop.” – Senior study author Ziyad Al-Aly, MD; Washington University School of Medicine